Histiocytic Disorder Follow-up Study

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05915208
Status
Recruiting
Apply to this trial

Conditions

  • Erdheim-Chester Disease
  • Histiocytosis
  • Langerhans Cell Histiocytosis
  • Malignant Histiocytoses
  • Rosai Dorfman Disease
  • Xanthogranuloma

Eligibility Criteria

Sex
ALL
Age
0 Years - 89 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Key Dates

Start date
Sep 1, 2022
Status verified
Jun 2025
Primary completion
Jul 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
6,000 participants (estimated)

Primary Outcome Measure

Chronic health conditions diagnosed after LCH diagnosis graded using the Common Terminology Criteria for Adverse Events (CTCAE), v5.0 (https://ctep.cancer.gov) [ Time Frame: From diagnosis of histiocytic disorder to age at completion of survey, assessed up to 200 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Gaurav Goyal, MD
[email protected]
1-866-438-1640

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies